Summary
Tissue factor is a cell surface glycoprotein responsible for initiating the extrinsic pathway of coagulation. Many tumor cell homogenates and intact tumor cells have been shown to contain tissue factor activity. Immunohistochemical studies show that many tumors associated with Trousseau's syndrome express tissue factor on their cell surfaces. Tumor cells shed membrane fragments which carry tissue factor that can account for the activation of the clotting system. Tumor cells also produce soluble substances that can induce tissue factor expression on host cells, such as endothelium and monocytes, at sites distant from the tumor. Although, all the functional TF molecules are localized on the outer cell membrane in many tumor cells, the procoagulant activity on the intact cell surface is largely dormant and can be greatly enhanced upon cell injury or damage. Tissue factor procoagulant activity on the cell surface can be modulated by alterations in the plasma membrane without loss of cell viability. Tissue factor activity on cell surfaces is largely regulated by a plasma inhibitor, tissue factor pathway inhibitor. This inhibitor binds to both functional and non-functional tissue factor/VIIa complexes on the cell surface and prevents non-functional tissue factor/VIIa complexes from becoming functional after cell injury or lysis. Heparin, but not warfarin, therapy is effective in preventing the occurrence of devasting thrombotic events in patients with Trousseau's syndrome and the reason(s) for this are still unknown.
Similar content being viewed by others
Abbreviations
- TF:
-
tissue factor
- DIC:
-
disseminated intravascular coagulation
- TFPI:
-
tissue factor pathway inhibitor
- FPA:
-
fibrinopeptide A
References
TrousseauA: Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris. The New Sydenham Society 3: 94, 1865
SackGH, LevinJ, BellWR: Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic and therapeutic features. Medicine 56: 1–37, 1977
BellWR, StarksenNF, TongS, PortefieldJK: Trousseau's syndrome. Devasting coagulopathy in the absence of heparin. Am J Med 79: 423–430, 1985
WomackWS, CastellanoCJ: Migratory thrombophlebitis associated with ovarian carcinoma. Am J Obstet Gynecol 63: 467–469, 1952
LiebermanJS, BorreroJ, UrdanetaE, WrightIS: Thrombophlebitis and cancer. JAMA 177: 542–545, 1961
FisherMM, HochbergLA, WilenskyND: Recurrent thrombophlebitis on obscure malignant tumors of lung. Report of four cases. JAMA 147: 1213–1216, 1951
PerlowS, DanielsJL: Venous thrombosis and obscure visceral carcinoma. Report of ten cases. Arch Int Med 97: 184–188, 1956
GordonSG, FranksJJ, LewisB: Cancer procoagulant A: a factor X-activating procoagulant from malignant tissue. Thromb Res 6: 127–137, 1975
GordonSG, CrossBA: A factor X-activating cysteine protease from malignant tissue. J Clin Invest 67: 1665–1671, 1981
vanDewaterL, TracyPB, AronsonD, MannKG, DvorakHF: Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 45: 5521–5525, 1985
SakaiT, NoguchiM, KisielW: Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin. Hemostasis 20: 125–135, 1990
Gordon SG, Chelladurai M: Non-tissue factor coagulants of cancer cells. Cancer Metastasis Rev, 1992, in press
DrakeTA, MorrisseyJH, EdgingtonT: Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Path 134: 1087–1097, 1989
FleckRA, RaoLVM, RapaportSI, VarkiN: Localization of human tissue factor antigen by immunostaining with monospecific polyclonal anti-human tissue factor antibody. Thromb Res 59: 421–437, 1990
WilliamsEB, KrishnaswamyS, MannKG: Zymogen/enzyme discrimination using peptide chloromethyl ketones. J Biol Chem 264: 7536–7545, 1989
WildgooseP, BerknerKL, KisielW: Synthesis, purification, and characterization of an Arg152→Glu site-directed mutant of recombinant human blood clotting factor VII. Biochemistry 29: 3413–3420, 1990
RaoLVM, RapaportSI: Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 85: 6687–6691, 1988
NemersonY, RepkeD: Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation cofactor. Thromb Res 40: 351–358, 1985
SeligshohnU, KasperCK, ØsterudB, RapaportSI: Activated factor VII. Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 53: 828–833, 1978
BrozeGJ, MajerusPW: Purification and properties of human coagulation factor VII. J Biol Chem 255: 1242–1247, 1980
KondoS, KisielW: Regulation of factor VIIa activity in plasma: Evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromb Res 46: 325–335, 1987
RaoLVM, RapaportSI: Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 69: 645–651, 1987
BrozeGJJr, WarrenLA, NovotnyWF, HiguchiDA, GirardTJ, MiletichJP: The lipoprotein associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its mechanism of action. Blood 71: 355–362, 1988
NemersonY: Tissue factor and hemostasis. Blood 71: 1–8, 1988
BachRR: Initiation of coagulation by tissue factor. CRC Crit Rev in Biochem 23: 339–368, 1988
MorrisseyJH, GregorySA, MackmanN, EdgingtonTS: Tissue factor regulation and gene organization. Oxford Surveys in Eukaryotic Genes 6: 67–84, 1989
RapaportSI: Inhibition of factor VIIa/tissue factor induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 73: 359–365, 1989
BrozeGJJr, GirardTJ, NovotnyWF: Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 29: 7539–7546, 1990
SandsetPM, AbildgaardU: Extrinsic pathway inhibitor — the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 21: 219–239, 1991
EisemanG, StefaminiM: Thromboplastic activity of leukemic white cells. Proc Soc Exp Biol Med 86: 763–765, 1954
O'Meara RAQ: Coagulative properties of cancers. Irish J Med Sci (series 6): 474–479, 1958
GralnickHR, AbrellE: Studies on the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Haematol 24: 89–99, 1973
DvorakHF, SengerDR, DvorakAM: Fibrin as a component of the tumor stroma: Origins and biological significance. Cancer Metastasis Rev 2: 41–73, 1983
RicklesFR, EdwardsRL: Activation of blood coagulation in Cancer: Trousseau's syndrome revisited. Blood 62: 14–31, 1983
DvorakHF: Abnormalities of hemostasis in malignancy. In: ColmanRW, HirshJ, MarderVJ, SalzmanEW (eds) Hemostasis and thrombosis. Basic principles and clinical practice. JB Lippincott Co, Philadelphia, 1987, pp 1143–1157
NaitoS, InoueS, KinjoM, TanakaK: Thromboplastic and fibrinolytic activities of cultured human gastric cancer cell lines. Gann 74: 240–247, 1983
FrancisJL, El-BaruniK, RoathOS, TaylorI: Factor X-activating activity in normal and malignant colorectal tissue. Thromb Res 52: 207–217, 1988
DoverR, GoetingNLM, TaylorI, RoathOS, FrancisJL: Factor X-activating activity in patients with colorectal carcinoma. Brit J Surg 74: 1122–1124, 1987
El-BaruniK, TaylorI, RoathS, FrancisJL: Factor X-activating procoagulant in normal and malignant breast tissue. Hematological Oncology 8: 323–332, 1990
SzczepanskiM, BardadinK, ZawadzkiJ, PypnoW: Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent. J Cancer Res Clin Oncol 114: 519–522, 1988
SilberbergJM, GordonS, ZuckerS: Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 49: 5443–5447, 1989
WijermansPW, RebelVI, OssenkoppeleGJ, HuijgensPC, LangenhuijsenMM: Combined procoagulant activity and proteolytic activity of acute promyelocytic leukemic cells: Reversal of the bleeding disorder by cell differentiation. Blood 73: 800–805, 1989
TanakaH, NaraharaN, KurabayashiH, SadakataH, AndohK, UchiyamaT, KobayashiN, MaekawaT: Studies on leukemic cell tissue factor. Thromb Res 53: 535–549, 1989
BauerKA, ConwayEM, BachR, KonigsbergWH, GriffinJD, DemetriG: Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 56: 425–430, 1989
ZeldisSM, NemersonY, PitlickFA: Tissue factor (thromboplastin): Localization to plasma membranes by peroxidase-conjugated antibodies. Science 175: 766–768, 1972
ZacharskiLR, HoyerLW, McIntyreOR: Immunologic identification of tissue factor synthesized by cultured fibroblasts. Blood 41: 671–678, 1973
Paulsen N, Bjorklid E, Giercksky KE: Immunohistochemical localization of tissue thromboplastin in placenta and some tissues of the gastrointestinal systems. Thromb Haemostas 50: 27a, 1983
WilcoxJN, SmithKM, SchwartzSM, GordonD: Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci 86: 2839–2843, 1989
ZacharskiLR, SchnedA, SorensonGD: Occurrence of fibrin and tissue factor antigen in small cell carcinoma of the lung. Cancer Res 43: 3963–3968, 1983
WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 65: 481–485, 1990
WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Indirect activation of blood coagulation in colon cancer. Thromb Haemostas 62: 1062–1066, 1989
CostantiniV, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM: Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 51: 349–353, 1991
WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Malignant melanoma. Interaction with coagulation and fibrinolysis pathwaysin situ. Am J Clin Pathol 3: 516–521, 1990
OrnsteinDL, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, HuntJ, RousseauSM, StumpDC: Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 68: 1061–1067, 1991
WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, MoritzTE, RousseauSM, StumpDC: Fibrin formation in vessel walls in hyperplastic and malignant prostate tissue. Cancer 67: 1377–1383, 1991
Callander NS, Rapaport SI: Trousseau's syndrome: Recognition, management, and pathogenesis, 1992, submitted
Callander NS, Varki N, Rao LVM: Immunohistochemical identification of tissue factor in solid tumors. Cancer, 1992, in press
ZacharskiLR, MemoliVA, RousseauSM: Coagulation-cancer interactionin situ in renal cell carcinoma. Blood 68: 394–399, 1986
WojtukiewiczMZ, ZacharskiLR, MemoliVA, KisielW, KudrykBJ, RousseauSM, StumpDC: Fibrinogen-fibrin transformationin situ in renal cell carcinoma. Anticancer Res 10: 579–582, 1990
WarrTA, RaoLVM, RapaportSI: Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 75: 1481–1489, 1990
DvorakHF, NagyJA, DvorakJT, DvorakAM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95–109, 1988
KenneyWE: The association of carcinoma in the body and tail of the pancreas with multiple venous thrombi. Surgery 14: 600–609, 1943
McKayDG, WahleGHJr: Disseminated thrombosis in colon cancer. Cancer 8: 970–978, 1955
FrickPG: Acute hemorrhagic syndrome with hypofibrino-genemia in metastatic cancer. Acta Haematol 16: 11–29, 1956
BlackPH: Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32: 75–199, 1980
DoljanskiF: Cell surface shedding. The Glycoconjugates IV: 155–187, 1982
DvorakHF, QuaySC, OrnsteinNS, DvorakAM, HahnP, BitzerAM, CarvalhoAC: Tumor shedding and coagulation. Science 212: 923–924, 1981
DvorakHF, Van DeWaterL, BitzerAM, DvorakAM, AndersonD, HarveyVS, BachR, DavisGL, DeWolfW, CarvalhoAC: Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 43: 4334–4342, 1983
BonaR, LeeE, RicklesF: Tissue factor apoprotein: Intracellular transport and expression in shed membrane vesicles. Thromb Res 48: 487–500, 1987
BastidaE, OrdinasA, EscolarG, JamiesonGA: Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 64: 177–184, 1984
GrignaniG, JamiesonGA: Tissue factor-dependent activation of platelets by cells and microvesicles of SK-OS-10 human osteogenic sarcoma cell line. Invasion Metastasis 7: 172–182, 1987
Gouault-HelimanM, ChardonE, SultanC, JossoF: The procoagulant factor in leukemic promyelocytes: Demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 30: 151–158, 1975
GuariniA, GugliottaL, TimonciniC, ChettiL, CataniL, RussoD, TuraS: Procoagulant activity and disseminated intravascular coagulation in acute non-lymphoid leukaemia. Scand J Haematol 34: 152–156, 1985
HendersonES: Acute leukemia general considerations. In: WilliamsWJ, BeutlerE, ErsleyAJ, LichtmanMA (eds) Hematology. McGraw-Hill, New York, 1983, pp 221–239
CarrJM, DvorakAM, DvorakHF: Circulating membrane vesicles in leukemic blood. Cancer Res 45: 5944–5951, 1985
KubotaT, AndohK, SadakataH, TanakaH, KobayashiN: Tissue factor released from leukemic cells. Thromb Haemostas 65: 59–63, 1991
WallJG, WeissRB, NortonL, PerloffM, RiceMA, KorzunAH, WoodWC: Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a cancer and leukemia group B study. Am J Med 87: 501–504, 1989
SaphnerT, TormeyDC, GrayR: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9: 286–294, 1991
GrimstadIA, PrydzH: Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells. Int J Cancer 41: 427–431, 1988
CozzolinoF, TorciaM, MilianiA, CarossinoAM, GiordaniR, CinottiS, FilimbertiE, SaccardiR, BernabelP, GuidiG, DiGuglielmoR, PistoiaV, FerrariniM, NawrothPP, SternD: Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 84: 240–250, 1988
BennicelliJL, EliasJ, KernJ, GuerryD: Production of interleukin-1 activity by cultured human melanoma cells. Cancer Res 49: 930–935, 1989
KockA, SchwarzT, UrbanskiA, PengZ, VitterleinM, MickscheM, AnselJC, KungHF, LugerTA: Expression and release of interleukin-1 by different human melanoma cell lines. J Natl Cancer Inst 81: 36–42, 1989
SatoK, FujiiY, KakiuchiT, KasanoK, ImamuraH, KondoY, ManoH, OkabeT, AsanoS, TakakuF: Faraneoplastic syndrome of hypercalcemia and leukocytosis caused by squamous carcinoma cells (T3M-1) producing parathyroid hormone-related protein, interleukin 1 alpha and granulocyte colony stimulating factor. Cancer Res 49: 4740–4756, 1989
TanakaM, KishiT: Induction of tissue factor by interleukin-2 in acute myelogenous leukemia (AML) cells. Growth Factors 4: 1–8, 1990
ClaussM, MurrayJC, ViannaM, deWallR, ThurstonG, NawrothP, GerlachH, GerlachM, BachR, FamillettiPC, SternD: A polypeptide factor produced by fibrosarcoma cells that induces endothelial cell tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem 265: 7078–7083, 1990
ClaussM, GerlachM, GerlachH, BrettJ, WangF, FamillettiPC, PanYC, OlanderJV, ConnollyDT, SternD: Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172: 1535–1545, 1990
NoguchiM, SakaiT, KisielW: Identification and partial purification of a novel tumor derived protein that induces tissue factor on cultured human endothelial cells. Biochem Biophys Res Commun 160: 222–227, 1989
RyanJ, GeczyC: Coagulation and the expression of cellmediated immunity. Immunol Cell Biol 65: 127–139, 1987
SemeraroN, MontemurroP, ConeseM, GiordanoD, StellaM, RestainoA, CagnazzoG, ColucciM: Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies. Int J Cancer 45: 251–254, 1990
ØsterudB, DueJJr: Blood coagulation in patients with benign and malignant tumors before and after surgery. Scand J Haematol 32: 258–263, 1984
Barbui T, Viero P, Cortelazzo S, Casarotto C, Colucci M, Semararo N: Increased production of mononuclear cell procoagulant activities in Hodgkin disease. Thromb Haemostas 50: 148a, 1983
EdwardsRL, RicklesFR, CronlundM: Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med 98: 917–928, 1981
DasmahapatraKS, CheungNK, SpillertC, LazaroE: An assessment of monocyte procoagulant activity in patients with solid tumors. J Surg Res 43: 158–163, 1987
DittmanW, MajerusP: Structure and function of thrombomodulin: A natural anticoagulant. Blood 75: 329–336, 1990
HartzellS, RyderK, LanahanA, LauLF, NathansD: Growth factor-responsive gene of murine BALB/c 3T3 cells encodes a protein homologous to human tissue factor. Mol Cell Biol 9: 2567–2573, 1989
AlmusFE, RaoLVM, PendurthiUR, QuattrochiL, RapaportSI: Mechanism for diminished tissue factor expression by endothelial cells cultured with heparin binding growth factor-1 and heparin. Blood 77: 1256–1262, 1991
RanganathanG, BlattiSP, SubramaniamM, FassD, MaihleNJ, GetzMJ: Cloning of murine tissue factor and regulation of gene expression by transforming growth factor type β1. J Biol Chem 266: 496–501, 1991
ArchipoffG, BeretzA, FreyssinetJ-M, Klein-SoyerC, BrissonC, CazenaveJ-P: Heterogeneous regulation of constitutive thrombomodulin or inducible tissue factor activities on the surface of human saphenous-vein endothelial cells in culture following stimulation by interleu-kin-1 tumour necrosis factor, thrombin or phorbol ester. Biochem J 273: 679–684, 1991
CrossmanDC, CarrDP, TuddenhamEGD, PearsonJD, McVeyJH: The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 265: 9782–9787, 1990
EdgingtonTS, MackmanN, BrandK, RufW: The structural biology of expression and function of tissue factor. Thromb Haemostas 66: 67–79, 1991
GregorySA, MorrisseyJH, EdgingtonTS: Regulation of tissue factor gene expression in the monocyte response to endotoxin. Mol Cell Biol 9: 2752–2755, 1989
FibachE, TrevesA, KorenbergA, RachmilewitzEA:In vitro generation of procoagulant activity by leukemic promyelocytes in response to cytotoxin drugs. Am J Hematol 20: 257–262, 1985
MaynardJR, DreyerBE, StemermanMB, PitlickFA: Tissue-factor coagulant activity of cultured human umbilical vein endothelial and smooth muscle cells and fibroblasts. Blood 50: 387–396, 1977
MaynardJR, HeckmanCA, PitlickFA, NemersonY: Association of tissue factor activity with the surface of cultured cells. J Clin Invest 55: 814–822, 1975
SchorerAE, RickPD, SwaimWR, MoldowCF: Structural features of endotoxin required for stimulation of endothelial cell tissue factor production: exposure of preformed tissue factor after oxidant-mediated endothelial cell injury. J Lab Clin Med 106: 38–42, 1985
DrakeTA, RufW, MorrisseyJH, EdgingtonTS: Functional tissue factor is entirely cell-surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 109: 389–395, 1989
RaoLVM, RobinsonT, HoangAD: Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in a suspension: A kinetic study. Thromb Haemostas 67: 654–659 1992
TaitJF, GibsonD, FujikawaK: Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem 262: 7944–7949, 1989
KondoS, NoguchiM, FunakoshiT, FujikawaK, KisielW: Inhibition of human factor VIIa-tissue factor activity by placental anticoagulant protein. Thromb Res 48: 449–459, 1987
GramzinskiRA, BrozeGJJr, CarsonSD: Human fibroblast tissue factor is inhibited by lipoprotein-associated coagulation inhibitor and placental anticoagulant protein but not by apolipoprotein A-II, Blood 73: 983–989, 1989
LeDT, RapaportSI, RaoLVM: Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 267: 15447–15454, 1992, submitted
BachR, RifkinDB: Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium. Proc Natl Acad Sci (USA) 87: 6955–6999, 1990
WalshJD, GeczyCL: Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose of cycloheximide. Thromb Haemostas 66: 552–558, 1991
Ryan J, Brett J, Kisiel W, Stern D: Tumor necrosis factor-induced endothelial cell tissue factor is principally associated with the subendothelial matrix. Blood 76: 2068a, 1990
CarsonSD, PirruccelloSJ, HaireWD: Tissue factor antigen and activity are not expressed on the surface of intact cells isolated from an acute promyelocytic leukemia patient. Thromb Res 59: 159–170, 1990
LindahlAK, SandsetPM, AbilgaardU, AndersonTR, HarbitzTB: High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 155: 389–393, 1989
RosenbergRD: The heparin-antithrombin system: a natural anticoagulant mechanism. In: ColmanRW, HirshJ, MarderVJ, SalzmanE (eds) Hemostasis and Thrombosis. Basic principles and clinical practice. JB Lippincott, Philadelphia, 1987, pp 1373–1392
LindahlU, ThunbergL, BackstromG, RiesenfeldJ, NordlingK, BjorkI: Extension and structural variability of the antithrombin-binding sequence in heparin. J Biol Chem 259: 12368–12376, 1984
SadowskiJA, BovillEG, MannKG: Warfarin and the metabolism and the function of vitamin K: In: PollerL (ed) Recent advances in blood coagulation. Churchill-Livingstone, Edinburgh, 1991, pp 93–118
Zivelin A, Rapaport SI, Rao LVM: tWarfarin but not heparin inhibited tissue factor induced disseminated intravascular coagulation. Thromb Haemostas 65: 1949a, 1991
SandsetPM, AbildgaardU, LarsenML: Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50: 803–813, 1988
NovotnyWF, BrownSG, MiletichJP, RadarDJ, BrozeGJJr: Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples. Blood 78: 387–393, 1991
WunT-C: Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: Synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 79: 430–438, 1992
LindahlAK, AbildgaardU, LarsenML, StaalesenR, HammerAKG, SandsetPM, NordfangO, BeckTC: Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. Thromb Res 62: 607–614, 1991
Lindahl AK, Abildgaard U, Larsen ML, Aamodt LM, Nordfang O, Beck TC: Extrinsic pathway inhibitor (EPI) and the post heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res (Suppl. XIV): 39–48, 1991
LindahlAK, JacobsenPB, SandsetPM, AbildgaardU: Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagulation and Fibrinolysis 2: 713–721, 1991
Warn-Cramer BJ, Maki SL, Rapaport SI: Heparin-releasable and platelet pools of tissue factor pathway inhibitor (TFPI) in rabbits. Blood 78: 220a, 1991
SproulEE: venous thrombosis: The frequency of carcinoma of the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 34: 566–585, 1938
JenningsWK, RussellWO: Phlebothrombosis associated with mucin-producing carcinomas of the tail and body of the pancreas. Arch Surg 56: 186–198, 1948
RohnerRF, PriorJT, SippleJH: Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli. A syndrome. Cancer 19: 1805–1812, 1966
PineoGF, RegoecziE, HattonMWC, BrainMC: The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med 82: 255–264, 1973
LaflerCJ, HinermanDL: A morphologic study of pancreatic carcinoma with reference to multiple thrombi. Cancer 14: 944–952, 1961
ChelladuraiM, HonnKV, WalzDA: HLA-DR is a procoagulant. Biochem Biophys Res Commu 178: 467–473, 1991
AltieriDC, MorrisseyJH, EdgingtonTS: Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci (USA) 85: 7462–7466, 1988
EtinginOR, SilversteinRL, FriedmanHM, HajjarDP: Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell 61: 657–662, 1990
AltieriDC, EtinginOR, FairDS, BrunckTK, GeltoskyJE, HajjarDP, EdgingtonTS: Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors. Science 254: 1200–1202, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mohan Rao, L.V. Tissue factor as a tumor procoagulant. Cancer Metast Rev 11, 249–266 (1992). https://doi.org/10.1007/BF01307181
Issue Date:
DOI: https://doi.org/10.1007/BF01307181